These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18593363)

  • 1. Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin.
    Aarts F; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP
    Cancer Biother Radiopharm; 2008 Jun; 23(3):301-9. PubMed ID: 18593363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.
    Aarts F; Hendriks T; Boerman OC; Koppe MJ; Oyen WJ; Bleichrodt RP
    Ann Surg Oncol; 2007 Nov; 14(11):3274-82. PubMed ID: 17653591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.
    Aarts F; Bleichrodt RP; de Man B; Lomme R; Boerman OC; Hendriks T
    Ann Surg Oncol; 2008 Nov; 15(11):3299-307. PubMed ID: 18712445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin.
    Aarts F; Koppe MJ; Hendriks T; van Eerd JE; Oyen WJ; Boerman OC; Bleichrodt RP
    Ann Surg Oncol; 2007 Feb; 14(2):533-40. PubMed ID: 17122992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis.
    Koppe MJ; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP
    J Nucl Med; 2006 Nov; 47(11):1867-74. PubMed ID: 17079821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study.
    Klaver YL; Hendriks T; Lomme RM; Rutten HJ; Bleichrodt RP; de Hingh IH
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S475-82. PubMed ID: 21837528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model.
    Klaver YL; Hendriks T; Lomme RM; Rutten HJ; Bleichrodt RP; de Hingh IH
    Br J Surg; 2010 Dec; 97(12):1874-80. PubMed ID: 20806291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can antibody galactosylation be used to improve radioimmunotherapy of induced peritoneal carcinomatosis of colonic origin in the rat?
    Aarts F; Hendriks T; Eek A; Oyen WJ; Bleichrodt RP; Boerman OC
    Cancer Biother Radiopharm; 2009 Feb; 24(1):29-34. PubMed ID: 19243245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
    J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.
    van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH
    Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New treatment of peritoneal carcinomatosis from colorectal cancer. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
    Iversen LH; Rasmussen PC; Laurberg S
    Ugeskr Laeger; 2007 Sep; 169(38):3179-81. PubMed ID: 17910824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: an experimental study.
    Klaver YL; Hendriks T; Lomme RM; Rutten HJ; Bleichrodt RP; de Hingh IH
    Ann Surg; 2011 Jul; 254(1):125-30. PubMed ID: 21502859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin].
    Berger Y; Zbar AP; Lebedyev A; Levi Y; Nevler A; Aderka D; Golan T; Purim O; Brenner B; Natur M; Gutman M
    Harefuah; 2014 Jun; 153(6):315-9, 368. PubMed ID: 25095601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
    Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
    Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer.
    Franko J; Gusani NJ; Holtzman MP; Ahrendt SA; Jones HL; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2008 Nov; 15(11):3065-72. PubMed ID: 18712450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urological procedures in patients with peritoneal carcinomatosis of colorectal cancer treated with HIPEC: morbidity and survival analysis.
    Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
    Anticancer Res; 2015 Jan; 35(1):295-300. PubMed ID: 25550563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
    Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
    Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.